# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 mi...
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming bina...